Q2 2025 Fennec Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Fennec Pharmaceuticals Inc (FENC) reported a 33% year-over-year revenue growth and 10% sequential growth, reaching net revenues of $9.7 million.
- PEDMARK has been added to the formulary of a large national oncology group, indicating growing recognition and adoption.
- The company has seen three consecutive quarters of growth, reflecting successful execution of its go-to-market strategy.
- Fennec Pharmaceuticals Inc (FENC) has expanded its Fennec HEARS patient assistance program, improving patient support and access.
- The launch of PEDMARQSI by Norgine in the EU is underway, with positive traction in the UK and Germany, promising future milestones and royalties.
- Operating expenses increased to approximately $11 million, driven by marketing investments and additional headcount.
- The company recorded $4.4 million in selling and marketing expenses, up from $2.9 million in the previous quarter.
- General and administrative expenses increased due to noncash stock compensation and ongoing litigation and intellectual property expenses.
- Cash and cash equivalents were reported at $18.7 million, indicating a need for careful cash management.
- The company faces challenges in ensuring compliance with FDA guidance against substituting PEDMARK with compounded versions.
Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals second-quarter 2025 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's conference is being recorded.
Now I would like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade.
Thank you, operator, and good morning, everyone. Thank you for joining us. We are pleased to host Fennec Pharmaceuticals' second quarter 2025 earnings conference call today. During which we will review our financial results as well as provide a general business update.
Joining me from Fennec this morning is our Chief Executive Officer and Board member, Jeff Hackman. Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.
Reference to these risks
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
